Neurodevelopmental outcomes in infants treated with intravitreal bevacizumab versus laser

[1]  K. Mireskandari,et al.  The effect of a single anti‐Vascular Endothelial Growth Factor injection on neonatal growth and organ development: In‐vivo study , 2018, Experimental eye research.

[2]  D. Moshfeghi,et al.  Outcomes of Intravitreal Bevacizumab and Diode Laser Photocoagulation for Treatment-Warranted Retinopathy of Prematurity. , 2018, Ophthalmic surgery, lasers & imaging retina.

[3]  Linh G. Ly,et al.  Neurodevelopmental Outcomes of Infants Born at <29 Weeks of Gestation Admitted to Canadian Neonatal Intensive Care Units Based on Location of Birth , 2018, The Journal of pediatrics.

[4]  K. Kennedy,et al.  Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity. , 2017, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.

[5]  Domenico Lepore,et al.  Follow-up to Age 4 Years of Treatment of Type 1 Retinopathy of Prematurity Intravitreal Bevacizumab Injection versus Laser: Fluorescein Angiographic Findings. , 2017, Ophthalmology.

[6]  M. Sharp,et al.  Counterbalanced Comparison of the BSID-II and Bayley-III at Eighteen to Twenty-two Months Corrected Age , 2017, Journal of developmental and behavioral pediatrics : JDBP.

[7]  Steven P. Miller,et al.  Severe retinopathy of prematurity predicts delayed white matter maturation and poorer neurodevelopment , 2017, Archives of Disease in Childhood: Fetal and Neonatal Edition.

[8]  A. Hutchinson,et al.  Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity: A Report by the American Academy of Ophthalmology. , 2017, Ophthalmology.

[9]  Linh G. Ly,et al.  Association of Patent Ductus Arteriosus Ligation With Death or Neurodevelopmental Impairment Among Extremely Preterm Infants , 2017, JAMA pediatrics.

[10]  Guoming Zhang,et al.  COMPARISON OF INTRAVITREAL INJECTION OF RANIBIZUMAB VERSUS LASER THERAPY FOR ZONE II TREATMENT-REQUIRING RETINOPATHY OF PREMATURITY , 2017, Retina.

[11]  F. Lefebvre,et al.  Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity , 2016, Pediatrics.

[12]  V. Bhat,et al.  Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. , 2016, The Cochrane database of systematic reviews.

[13]  Wei-Chi Wu,et al.  Neurodevelopmental Outcomes in Infants with Retinopathy of Prematurity and Bevacizumab Treatment , 2016, PloS one.

[14]  Chang Sik Cho,et al.  Intravitreally Injected Anti-VEGF Antibody Reduces Brown Fat in Neonatal Mice , 2015, PloS one.

[15]  Wei-Chi Wu,et al.  Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity. , 2015, JAMA ophthalmology.

[16]  Y. Hwang,et al.  Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes , 2014, Eye.

[17]  K. Mireskandari,et al.  Type I ROP, treatment with bevacizumab versus laser: comparison of visual function, structural outcome and frequency of follow-up , 2014 .

[18]  Miguel Cordero,et al.  Validity of the Ages and Stages Questionnaires in Term and Preterm Infants , 2013, Pediatrics.

[19]  M. Martinez-Castellanos,et al.  LONG-TERM EFFECT OF ANTIANGIOGENIC THERAPY FOR RETINOPATHY OF PREMATURITY Up to 5 Years of Follow-up , 2013, Retina.

[20]  A. Chuang,et al.  BEAT-ROP refraction data at age 2 years , 2013 .

[21]  C. Borradori-Tolsa,et al.  Outcome at two years of age in a Swiss national cohort of extremely preterm infants born between 2000 and 2008 , 2012, BMC Pediatrics.

[22]  Nancy Bayley,et al.  BAYLEY SCALES OF INFANT AND TODDLER DEVELOPMENT, THIRD EDITION (BAYLEY-III) , 2014 .

[23]  Charles DiMaggio,et al.  Long-term Differences in Language and Cognitive Function After Childhood Exposure to Anesthesia , 2012, Pediatrics.

[24]  M. D. Olson,et al.  Attention-deficit/hyperactivity disorder after early exposure to procedures requiring general anesthesia. , 2012, Mayo Clinic proceedings.

[25]  Sarah J. Erickson,et al.  Comparison of the Bayley II Mental Developmental Index and the Bayley III cognitive scale: are we measuring the same thing? , 2012, Acta paediatrica.

[26]  Darrell R. Schroeder,et al.  Cognitive and Behavioral Outcomes After Early Exposure to Anesthesia and Surgery , 2011, Pediatrics.

[27]  Alice Z Chuang,et al.  Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. , 2011, The New England journal of medicine.

[28]  B. Schmidt,et al.  Using a Count of Neonatal Morbidities to Predict Poor Outcome in Extremely Low Birth Weight Infants: Added Role of Neonatal Infection , 2009, Pediatrics.

[29]  Lois E. H. Smith.  Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture. , 2008, Investigative ophthalmology & visual science.

[30]  J. Haigh.  Role of VEGF in organogenesis , 2008, Organogenesis.

[31]  Nehal A Parikh,et al.  Intensive care for extreme prematurity--moving beyond gestational age. , 2008, The New England journal of medicine.

[32]  B. Dan,et al.  A report: the definition and classification of cerebral palsy April 2006 , 2007, Developmental medicine and child neurology. Supplement.

[33]  D. Eliott,et al.  Near confluent laser photocoagulation for the treatment of threshold retinopathy of prematurity. , 2005, Archives of ophthalmology.

[34]  W. Tasman,et al.  Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. , 2004, Archives of ophthalmology.

[35]  A. Fielder,et al.  Preliminary results of treatment of eyes with high-risk prethreshold retinopathy of prematurity in the early treatment for retinopathy of prematurity randomized trial. , 2003, Archives of ophthalmology.

[36]  M. Lynn,et al.  Clinical outcome of confluent laser photoablation for retinopathy of prematurity. , 2002, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.

[37]  R. Palisano,et al.  Development and reliability of a system to classify gross motor function in children with cerebral palsy , 1997, Developmental medicine and child neurology.

[38]  G. Aylward.  Bayley Scales of Infant and Toddler Development , 2017 .

[39]  A. Chuang,et al.  Refractive Outcomes at Age 2½ Years in the Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity Trial A Randomized Clinical Trial , 2014 .

[40]  Craig A. Albers,et al.  Third Edition. San Antonio, TX: Harcourt Assessment - Test Review: Bayley, N. (2006). Bayley Scales of Infant and Toddler Development , 2014 .

[41]  Jane Squires,et al.  Ages & Stages Questionnaires[R], Third Edition (ASQ-3[TM]): A Parent-Completed Child-Monitoring System. , 2009 .